Karen Chagin

1.2k total citations
17 papers, 345 citations indexed

About

Karen Chagin is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Karen Chagin has authored 17 papers receiving a total of 345 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Karen Chagin's work include CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (11 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Karen Chagin is often cited by papers focused on CAR-T cell therapy research (13 papers), Immunotherapy and Immune Responses (11 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Karen Chagin collaborates with scholars based in United States, Canada and Netherlands. Karen Chagin's co-authors include Malini Iyengar, Elliot Norry, Michéle David, Kalpana Bakshi, Michele P. Lambert, Dana C. Matthews, Rafael G. Amado, Julián Sevilla, Jenny M. Despotovic and Lakshmanan Krishnamurti and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of Oncology.

In The Last Decade

Karen Chagin

17 papers receiving 340 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen Chagin United States 9 181 150 105 67 58 17 345
Koichi Onodera Japan 11 67 0.4× 79 0.5× 40 0.4× 30 0.4× 63 1.1× 38 264
Roberta Gonella Italy 10 115 0.6× 80 0.5× 61 0.6× 36 0.5× 61 1.1× 17 257
Elliot Norry United States 10 316 1.7× 23 0.2× 172 1.6× 107 1.6× 75 1.3× 31 371
Thomas Broughton United Kingdom 10 222 1.2× 22 0.1× 218 2.1× 60 0.9× 69 1.2× 11 406
Patricia Kropf United States 9 59 0.3× 138 0.9× 49 0.5× 25 0.4× 193 3.3× 26 341
Lorenz Jost Switzerland 8 142 0.8× 18 0.1× 99 0.9× 102 1.5× 79 1.4× 11 342
Hoyoung Lee South Korea 4 138 0.8× 32 0.2× 115 1.1× 16 0.2× 31 0.5× 6 201
Natalia M. Tijaro-Ovalle United States 5 271 1.5× 27 0.2× 319 3.0× 24 0.4× 80 1.4× 9 432
Chaozeng Si China 11 47 0.3× 35 0.2× 46 0.4× 63 0.9× 182 3.1× 30 281
Susanne Strifler Germany 8 179 1.0× 243 1.6× 20 0.2× 15 0.2× 189 3.3× 16 345

Countries citing papers authored by Karen Chagin

Since Specialization
Citations

This map shows the geographic impact of Karen Chagin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Chagin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Chagin more than expected).

Fields of papers citing papers by Karen Chagin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Chagin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Chagin. The network helps show where Karen Chagin may publish in the future.

Co-authorship network of co-authors of Karen Chagin

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Chagin. A scholar is included among the top collaborators of Karen Chagin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Chagin. Karen Chagin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
McKean, Meredith, Matthew Carabasi, Mark N. Stein, et al.. (2022). Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC.. Journal of Clinical Oncology. 40(6_suppl). 94–94. 23 indexed citations
2.
Barrett, David M., Karen Chagin, Thomas J. Fountaine, et al.. (2022). TmPSMA-02: A CD2 endodomain containing double armored PSMA CAR T with enhanced efficacy and lower immune toxicity.. Journal of Clinical Oncology. 40(6_suppl). 158–158. 4 indexed citations
3.
Gladney, Whitney L., Adina Vultur, Michael T. Schweizer, et al.. (2022). 335 Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells. Regular and Young Investigator Award Abstracts. A353–A353. 5 indexed citations
4.
Shah, Payal D., Omid Hamid, Alfred L. Garfall, et al.. (2021). Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors.. Journal of Clinical Oncology. 39(15_suppl). e14513–e14513. 30 indexed citations
5.
Carabasi, Matthew, Meredith McKean, Mark N. Stein, et al.. (2021). PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.. Journal of Clinical Oncology. 39(15_suppl). 2534–2534. 9 indexed citations
6.
Stadtmauer, Edward A., Thomas Faitg, Daniel E. Lowther, et al.. (2019). Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. Blood Advances. 3(13). 2022–2034. 69 indexed citations
7.
Lam, Vincent K., David S. Hong, John V. Heymach, et al.. (2018). Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.. Journal of Clinical Oncology. 36(15_suppl). 3056–3056. 8 indexed citations
8.
D’Angelo, Sandra P., Mihaela Druta, David A. Liebner, et al.. (2018). Pilot study of NY-ESO-1c259 T cells in advanced myxoid/round cell liposarcoma.. Journal of Clinical Oncology. 36(15_suppl). 3005–3005. 14 indexed citations
9.
Hong, David S., Marcus O. Butler, Anthony J. Olszanski, et al.. (2018). Initial safety assessment of MAGE-A4 SPEAR T-cells. Annals of Oncology. 29. viii412–viii412. 4 indexed citations
10.
Hong, David S., Marcus O. Butler, Ryan J. Sullivan, et al.. (2017). A phase I single arm, open label clinical trial evaluating safety of MAGE-A10c796T in subjects with advanced or metastatic head and neck, melanoma, or urothelial tumors (NCT02989064).. Journal of Clinical Oncology. 35(15_suppl). TPS3098–TPS3098. 3 indexed citations
11.
Shantakumar, Sumitra, Beth Nordstrom, Susan A. Hall, et al.. (2017). Prescriber Compliance With Liver Monitoring Guidelines for Pazopanib in the Postapproval Setting: Results From a Distributed Research Network. Journal of Patient Safety. 15(1). 55–60. 2 indexed citations
12.
13.
14.
D’Angelo, Sandra P., Mihaela Druta, George D. Demetri, et al.. (2017). A pilot study of NY-ESO-1c259 T cells in subjects with advanced myxoid/round cell liposarcoma (NCT02992743).. Journal of Clinical Oncology. 35(15_suppl). TPS3097–TPS3097. 2 indexed citations
15.
Mackall, Crystal L., William D. Tap, John Glod, et al.. (2017). Open label, non-randomized, multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259t in HLA-A2+ patients with synovial sarcoma (NCT01343043).. Journal of Clinical Oncology. 35(15_suppl). 3000–3000. 18 indexed citations
16.
Shantakumar, Sumitra, Beth Nordstrom, Luc Djoussé, et al.. (2016). Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network. Cancer Chemotherapy and Pharmacology. 78(3). 559–566. 15 indexed citations
17.
Bussel, James B., Purificación García de Miguel, Jenny M. Despotovic, et al.. (2015). Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. The Lancet Haematology. 2(8). e315–e325. 133 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Koichi Onodera Breakdown of academic impact, for papers by Roberta Gonella Breakdown of academic impact, for papers by Elliot Norry Breakdown of academic impact, for papers by Thomas Broughton Breakdown of academic impact, for papers by Patricia Kropf Breakdown of academic impact, for papers by Lorenz Jost Breakdown of academic impact, for papers by Hoyoung Lee Breakdown of academic impact, for papers by Natalia M. Tijaro-Ovalle Breakdown of academic impact, for papers by Chaozeng Si Breakdown of academic impact, for papers by Susanne Strifler
Rankless by CCL
2026